Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 122

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 122
---
, and cancer advocacy groups to advance ARB’s development and adoption. Engaging with the broader oncology community can foster support for ARB’s innovative approach to cancer treatment. We also plan to engage with major pharmaceutical companies regarding existing cancer therapy products in the market, aiming to collaborate and integrate our combination therapy nano-ARB with approved treatments. This collaboration aims to facilitate lower doses, improve toxicity profiles, enhance treatment efficacy, and reduce resistance to current therapies. |

By adhering to this multi-path strategy,
we are planning to ensure that the ARB project is optimally positioned to navigate the complexities of the oncology field, from developmental
hurdles to regulatory approvals and market entry, aligning our efforts with the ultimate goal of transforming cancer treatment paradigms.

In this regard, we note that there can be no assurance
that we will be able to secure above referenced development partnerships or collaborations. However, we do not rely on public funding
and continue to pursue multiple funding strategies to support our development programs. If we are unable to successfully contract with
third parties for development support, we may need to target less indications and/or raise additional funds to continue advancing our
product candidates.

<div align='center'>78</div>

Manufacturing

Development plan and Chemistry, Manufacturing, and Controls (CMC)

CMC activities are centered on the development
of manufacturing methods, scaling up processes, and preparing Nano-Mupirocin for clinical trials. We do not own or operate, and currently
have no plans to establish, any manufacturing facilities.

We have engaged, and currently rely on, a
single third-party CMO, STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation and an affiliated company of WuXi AppTec a global
pharmaceutical CRDMO providing integrated drug discovery, development & manufacturing services across Asia, Europe & North America.,
for the supply of our product candidates for use in our preclinical studies and future clinical trials. Should our CMO become unavailable
to us for any reason, we believe that there are a number of potential replacements, although we would incur delay and cost in identifying
and qualifying such replacements. We maintain a master services agreement with STA Pharmaceuticals pursuant to which it has agreed to
provide biologics development and manufacturing services on a per-project basis. We may terminate the master services agreement at any
time for convenience in accordance with the terms of the agreement. The agreement includes confidentiality and intellectual property
provisions to protect our proprietary rights related to our product candidates. While any reduction or halt